Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Javier CortésSung-Bae KimWei-Pang ChungSeock-Ah ImYeon Hee ParkRoberto HeggMin Hwan KimLing-Ming TsengVanessa PetryChi-Feng ChungHiroji IwataErika HamiltonCurigliano GiuseppeBinghe XuChiun-Sheng HuangJee Hyun KimJoanne W Y ChiuJose Luiz PedriniCaleb LeeYali LiuJillian CathcartEmarjola BakoSunil VermaSara A Hurvitznull nullPublished in: The New England journal of medicine (2022)
Among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, the risk of disease progression or death was lower among those who received trastuzumab deruxtecan than among those who received trastuzumab emtansine. Treatment with trastuzumab deruxtecan was associated with interstitial lung disease and pneumonitis. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast03 ClinicalTrials.gov number, NCT03529110.).